Seamus Fernandez
Stock Analyst at Guggenheim
(4.80)
# 78
Out of 5,179 analysts
125
Total ratings
60.82%
Success rate
55.03%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GENB Generate Biomedicines | Initiates: Buy | $30 | $11.69 | +156.74% | 1 | Mar 24, 2026 | |
| APGE Apogee Therapeutics | Maintains: Buy | $130 → $160 | $77.94 | +105.29% | 9 | Mar 24, 2026 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $25 → $30 | $13.47 | +122.72% | 3 | Mar 19, 2026 | |
| TENX Tenax Therapeutics | Maintains: Buy | $25 → $34 | $14.75 | +130.51% | 4 | Mar 16, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $34 → $35 | $21.44 | +63.25% | 4 | Feb 27, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $140 → $143 | $77.00 | +85.71% | 4 | Feb 27, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $72 | $59.73 | +20.54% | 14 | Feb 6, 2026 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $27 | $4.82 | +460.17% | 1 | Feb 3, 2026 | |
| PCVX Vaxcyte | Reiterates: Buy | $116 | $54.25 | +113.82% | 5 | Feb 2, 2026 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,163 → $1,161 | $893.95 | +29.87% | 23 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $140 | $45.04 | +210.83% | 3 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $77 → $88 | $28.28 | +211.17% | 5 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $46.84 | - | 1 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $11 | $5.61 | +96.08% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.13 | - | 4 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $23.80 | - | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $122 | $121.56 | +0.36% | 14 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $54.54 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.02 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $35.49 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $149.89 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.60 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $3.52 | +1,434.09% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $30.29 | +48.56% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $193.82 | -80.39% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $27.44 | +38.48% | 3 | Jan 31, 2018 |
Generate Biomedicines
Mar 24, 2026
Initiates: Buy
Price Target: $30
Current: $11.69
Upside: +156.74%
Apogee Therapeutics
Mar 24, 2026
Maintains: Buy
Price Target: $130 → $160
Current: $77.94
Upside: +105.29%
Amylyx Pharmaceuticals
Mar 19, 2026
Maintains: Buy
Price Target: $25 → $30
Current: $13.47
Upside: +122.72%
Tenax Therapeutics
Mar 16, 2026
Maintains: Buy
Price Target: $25 → $34
Current: $14.75
Upside: +130.51%
Arcutis Biotherapeutics
Feb 27, 2026
Maintains: Buy
Price Target: $34 → $35
Current: $21.44
Upside: +63.25%
Rhythm Pharmaceuticals
Feb 27, 2026
Maintains: Buy
Price Target: $140 → $143
Current: $77.00
Upside: +85.71%
Bristol-Myers Squibb Company
Feb 6, 2026
Maintains: Buy
Price Target: $62 → $72
Current: $59.73
Upside: +20.54%
Sagimet Biosciences
Feb 3, 2026
Initiates: Buy
Price Target: $27
Current: $4.82
Upside: +460.17%
Vaxcyte
Feb 2, 2026
Reiterates: Buy
Price Target: $116
Current: $54.25
Upside: +113.82%
Eli Lilly and Company
Jan 20, 2026
Maintains: Buy
Price Target: $1,163 → $1,161
Current: $893.95
Upside: +29.87%
Jan 20, 2026
Maintains: Buy
Price Target: $90 → $140
Current: $45.04
Upside: +210.83%
Jan 16, 2026
Maintains: Buy
Price Target: $77 → $88
Current: $28.28
Upside: +211.17%
Dec 9, 2025
Downgrades: Neutral
Price Target: n/a
Current: $46.84
Upside: -
Nov 18, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $5.61
Upside: +96.08%
Oct 23, 2025
Downgrades: Neutral
Price Target: n/a
Current: $7.13
Upside: -
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $23.80
Upside: -
Jan 17, 2025
Maintains: Buy
Price Target: $130 → $122
Current: $121.56
Upside: +0.36%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $54.54
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.02
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $35.49
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $149.89
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.60
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $3.52
Upside: +1,434.09%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $30.29
Upside: +48.56%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $193.82
Upside: -80.39%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $27.44
Upside: +38.48%